PARADIGM4

Trending Articles

  1. Thermo Fisher Scientific officially opens US oral solid dose testing and R&D facility The company's further expansion in the Bend, Oregon area will assist its pharmaceutical clients in the early development of oral solid dosage (OSD) forms
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    CDMO insights: development and manufacture of a highly potent OSD product In today’s pharmaceutical landscape, contract development and manufacturing organisations (CDMOs) are ubiquitous. Prior to the CDMO boom in the 1990s, however, this wasn’t...
  3. Gerresheimer acquires Bormioli Pharma Group through Blitz LuxCo Sarl merger Gerresheimer and Bormioli Pharma will merge to provide the biotech and pharmaceutical industries with primary packaging solutions, dosing systems, closure solutions and...
  4. Accumulus Synergy teams up with CEPI to expedite the vaccine regulatory approval process Through Accumulus' cloud-based technology, the two organisations aim to accelerate the accessibility of data for the regulatory approval process of vaccines globally, enhancing...
  5. Manufacturing Chemist Stand Side with Enzene Biosciences at CPHI Milan 2024 We discover what exhibitors at CPHI Milan 2024 are showcasing LIVE!

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

Related Content

Regulatory

Multidimensional data analysis platforms: meeting new FDA calls for consistent evidence from CGT developers

Recent news that the US Food and Drug Administration (FDA) will ask cell and gene therapy (CGT) developers to provide more consistent evidence with their submissions has resulted in drug makers delaying development plans — and working on new ways to address the agency’s concerns.<sup>1</sup> Paradigm4's Marilyn Matz, CEO and cofounder, and Zachary Pitluk, VP of Life Sciences and Healthcare, report
Research & Development

The increasing power of single-cell omics: changing the future of medicine

Advances in the single-cell genomic analysis of cells and tissues, including the required computational methods, have now put systematic, high-resolution and comprehensive reference maps of all human cells within our reach. Paradigm4's Marilyn Matz, CEO and cofounder, and Dr Zachary Pitluk, VP of Life Sciences and Healthcare, report
Research & Development

54gene enlists Paradigm4 app for African Health Information Ecosystem

54gene aims to utilise African health data in global genomics research to improve healthcare worldwide
Research & Development

Paradigm4 launches app for large-scale data analysis

The app enables users to assess biological hypotheses for target evaluation, disease progression, and precision medicine
Subscribe now